11月5日，第八届中国国际进口博览会（以下简称进博会）首日，阿斯利康与青岛高新技术产业开发区 管理委员会签署合作协议，宣布将追加投资约1.36亿美元，用以扩大青岛生产供应基地产能。同时还宣 布青岛基地项目采用节能技术助力实现近零碳运营。 今年是阿斯利康第八次参加进博会，多个疾病领域的创新疗法亮相展台，过去七年共带来18款"进博宝 宝"，覆盖呼吸、肾脏、消化、罕见病、自体免疫及肿瘤等多个领域，为患者带来更多治疗方案选择。 阿斯利康全球执行副总裁、国际业务负责人尹思睿（Iskra Reic）表示："我们始终致力于深耕中国，与 合作伙伴携手共进，助力中国成为全球医疗健康创新的重要枢纽。本次在进博会上宣布的青岛基地扩建 项目，体现了我们对中国创新生态的信心，以及携手推动科学进步与共同健康的愿景。" （文章来源：科技日报） 据介绍，阿斯利康在华的三大生产供应基地分别位于无锡、泰州和青岛。目前，无锡基地已实现了 100%使用可再生能源的目标，并成为中国行业内率先使用清洁供热创新解决方案的生产供应基地，获 得碳中和承诺认证。泰州基地的碳排放较2015年减少97.5%。目前尚在建设中的青岛基地也预计在投产 之后实现近零碳运营 ...

Group 1 - The core viewpoint of the article highlights the successful debut of Jinfang Pharmaceutical on the Hong Kong Stock Exchange, with a significant stock price increase of 106.5% on its first trading day, closing at HKD 42.1 per share and achieving a total market capitalization of HKD 15.03 billion [1] - Jinfang Pharmaceutical, established in 2017, focuses on the development of innovative therapies for oncology, autoimmune, and inflammatory diseases, with a pipeline that includes 8 candidate products, 5 of which are in clinical development [1] - Financial data indicates that the company's revenues for the years 2023-2024 and the first four months of 2025 were HKD 73.734 million, HKD 105 million, and HKD 82.149 million respectively, while the losses for the same periods were HKD 508 million, HKD 678 million, and HKD 66.624 million [1]

Core Viewpoint - Conade Biopharma (CNTB) experienced a 5.06% increase in stock price, reaching $1.818 per share, with a total market capitalization of $101 million as of August 22 [1] Financial Performance - As of June 30, 2025, Conade Biopharma reported total revenue of $48,000, representing a 99.8% year-over-year decrease [1] - The company recorded a net loss attributable to shareholders of $23.171 million, which is a 476.52% year-over-year decline [1] Company Overview - Conade Biopharma Holdings Limited is a biopharmaceutical company with clinical-stage products and a global presence, focusing on developing innovative therapies through its proprietary T-cell function modulation platform to improve the quality of life for patients with inflammatory immune diseases [1]

本文源自：金融界 作者：行情君 8月5日，君实生物(01877)盘中上涨32.83%，截至15:54，报31.96元/股，成交11.06亿元。 上海君实生物医药科技股份有限公司主要业务是发现、开发和商业化创新疗法，特别是在肿瘤免疫疗 法、自身免疫系统疾病、慢性代谢类疾病、神经系统疾病、感染类疾病等治疗方面。公司拥有卓越的创 新药物发现能力、先进的生物技术研发、全产业链大规模生产技术和极具市场潜力的在研药品组合。 截至2025年一季报，君实生物营业总收入5.01亿元、净利润-2.35亿元。 ...